Mobile

A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase II Study to Assess The Efficacy of AZD9056 (single oral 400 mg dose) when Administered for 4 Weeks in Patients with M...

Mise à jour : Il y a 4 ans
Référence : EUCTR2005-004110-32

A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase II Study to Assess The Efficacy of AZD9056 (single oral 400 mg dose) when Administered for 4 Weeks in Patients with Moderate to Severe COPD

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of the study is to determine the efficacy of AZD9056 (single oral 400 mg dose) in moderate to severe COPD patients during a 4-week treatment period.

Critère d'inclusion

  • Chronic Obstructive Pulmonary Disease

Liens